Overview

Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients

Status:
Not yet recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

Single center, randomized, open-label, baseline-controlled study evaluating the use of a Sciton fractionated ablative laser in the treatment of Hidradenitis Suppurativa (HS) scarring.

Phase:

N/A

Details

Lead Sponsor:

Montefiore Medical Center

Treatments:

Hydrocortisone
Hydroquinone
Tretinoin